arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Marker Therapeutics, Inc.

MRKR
$1.12 ▼ -0.01 (-0.88%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
72 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

Marker Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $21.6M
Dividend Yield
Revenue Growth 115.3%
Op. Margin None
ROIC -23.3%
FCF / Share $-0.07
Trailing P/E
Price / Book 1.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$751.69K
↑ +115.3%
Net Income Profit after all expenses
$-3.18M
↑ +28.5%
Operating Margin Operating profit as % of sales
-173.3%
↑ +65.0% 0th
FCF / Share Free cash flow per share
$-0.07
↑ +85.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
12
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 26 years · 72 quarters